Mary Shaver-Lewis, MD
Nephrology · Conway, ARNPI 1497746341
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.4% of the total across 491 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 491 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Travere Therapeutics, Inc.$849
- Mallinckrodt Hospital Products Inc.$753
- AstraZeneca$719
- Vifor Pharma, Inc.$702
- OPKO Pharmaceuticals, LLC$641
- plus $4K from 20 others
What the payments were for
- Food & beverage$8,98692%
- Education$7428%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 117 | $2,148 |
| Travere Therapeutics, Inc. | 43 | $849 |
| Mallinckrodt Hospital Products Inc. | 30 | $753 |
| AstraZeneca | 36 | $719 |
| Vifor Pharma, Inc. | 35 | $702 |
| OPKO Pharmaceuticals, LLC | 39 | $641 |
| GSK | 42 | $553 |
| Novartis | 18 | $513 |
| Bayer | 25 | $445 |
| Fresenius USA Marketing, Inc. | 19 | $368 |
| Aurinia Pharma U.S., Inc. | 12 | $271 |
| Ardelyx, Inc. | 7 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $238 |
| Otsuka America Pharmaceutical, Inc. | 10 | $237 |
| Akebia Therapeutics Inc | 9 | $172 |
| Medtronic | 3 | $170 |
| Mallinckrodt Enterprises LLC | 6 | $146 |
| Ultragenyx Pharmaceutical Inc. | 6 | $133 |
| Calliditas Therapeutics US Inc. | 5 | $131 |
| ANI Pharmaceuticals, Inc. | 6 | $117 |
| Boehringer Ingelheim | 3 | $47 |
| Kyowa Kirin, Inc. | 2 | $39 |
| Lilly USA, LLC | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Vantive US Healthcare LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,728 in reported general payments places this provider in the 90th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 21 | $953,240 |
| RayaldeeCalcifediol | 61 | $83,062 |
| FarxigaDapagliflozin Propanediol | 69 | $40,186 |
| VeltassaPatiromer Calcium Sorbitex | 31 | $34,802 |
| ProsolParenteral Amino Acid 20% No.1 | 177 | $27,685 |
| AuryxiaFerric Citrate | 11 | $21,777 |
| Sevelamer Carbonate | 81 | $16,617 |
| KerendiaFinerenone | 16 | $13,142 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $10,723 |
| Repatha SureclickEvolocumab | 14 | $7,857 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,385 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 24 | $6,805 |
| JardianceEmpagliflozin | 12 | $6,036 |
| Nifedipine ErNifedipine | 233 | $5,289 |
| Cinacalcet Hcl | 39 | $4,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $238 | $953,24021 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $641 | $83,06261 claims |
| AstraZenecaFarxiga, Lokelma | $719 | $50,90883 claims |
| Akebia Therapeutics IncAuryxia | $172 | $21,77711 claims |
| BayerKerendia | $445 | $13,14216 claims |
| GSKTrelegy Ellipta | $553 | $7,38512 claims |
| Boehringer IngelheimJardiance | $47 | $6,03612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 85 nephrology providers in Arkansas.
Other nephrology in Conway
- Vikas VujjiniConway$3K
- Drew HeipleRussellville$236K
- Luis JuncosLittle Rock$66K
- John HeifnerLittle Rock$45K
- Shaker QaqishNorth Little Rock$16K
- Michael GerschHot Springs$10K
- Clinton EdwardsJonesboro$8K
- Hania Al-ShahrouriFort Smith$8K
- Mashhud MirzaMarion$7K
- John ArthurLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.